Earnings ·
Definium Therapeutics reported second quarter 2026 financial results and announced positive topline results from its…
MNMDMind Medicine (MindMed) Inc.
Definium Therapeutics reported second quarter 2026 financial results and announced positive topline results from its Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), meeting primary and secondary efficacy endpoints with a statistically significant improvement in MADRS scores. The company completed an underwritten public offering of approximately 23.7 million common shares for $805 million in gross proceeds, bringing cash, cash equivalents, and investments to $1.1 billion as of June 30, 2026. Net loss for the quarter was $159.0 million, significantly impacted by an $86.2 million non-cash increase in warrant liability fair value. The company also provided updates on its pipeline, including completed enrollment in Phase 3 Voyage and Panorama studies for generalized anxiety disorder (GAD) and initiated enrollment in the Phase 3 Ascend study for MDD. Definium Therapeutics is a late-stage clinical biopharmaceutical company developing psychedelic therapeutics for psychiatric disorders.